Topic: bladder cancer

Keytruda packaging

Merck ends Keytruda bladder cancer trial as endpoint met early

Merck has cut short its Phase III trial of checkpoint inhibitor Keytruda in advanced bladder cancer, saying it hit its endpoint, and so is moving on to present the data to regulators. This is particularly good news for the drugmaker since it is playing catch-up to competitors Roche and Bristol-Myers Squibb for this condition.